Authors
Yi Zhang, Hu Zhou, Junling Zhuang, Zhongxing Jiang, Dengshu Wu, Linhua Yang, Qian Jiang, Huanling Zhu, Xin Du, Wei Li, Aili He, Jinwen Huang, Yan Li, Xiuli Wang, Qingchi Liu, Yuqing Chen, Sujun Gao, Fei Li, Yarong Li, Wen Wu, Feng Zhang, Zhijian Xiao, Jie Jin, ZGJAK002/016 investigators
Published in
Clinical lymphoma, myeloma & leukemia. Oct 15, 2026. Epub Oct 15, 2026.
Abstract
Myelofibrosis (MF) is driven by JAK/STAT dysregulation. Gecacitinib, a novel JAK/ACVR1 inhibitor, is recently approved in China.
This study used a matching-adjusted indirect comparison (MAIC) to compare gecacitinib versus ruxolitinib and pelabresib-ruxolitinib in JAK inhibitor-naive MF. Individual patient data (IPD) from ZGJAK002/016 (gecacitinib, n = 137) were weighted to match aggregated data from COMFORT-I/II, SIMPLIFY-1, A2202, MANIFEST-2 (ruxolitinib and pelabresib-ruxolitinib arms). Outcomes included SVR35, TSS50, HGB improvement, and safety.
After matching baseline characteristics, gecacitinib showed better efficacy in 24-week SVR35 and TSS50 than most ruxolitinib groups, with lower risks of anemia, neutropenia, and treatment discontinuation due to adverse events (AEs). Versus pelabresib-ruxolitinib, gecacitinib had similar SVR35 (59.0% vs. 65.9%, OR 0.74, P = .27), numerically higher TSS50 rates (59.9% vs. 52.3%, OR 1.36, P = .24), but better hemoglobin improvement (HGB ≥ 1.5 g/dL, 26.4% vs. 10.7%, OR 2.98, P = .0012), lower rates of AEs and AE-related discontinuations (RD -0.06, P = .033).
Gecacitinib may offer advantages over ruxolitinib and comparable efficacy but better tolerability than pelabresib-ruxolitinib in JAK inhibitor-naive MF.
PMID:
43052092
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0